Dec. 21 (UPI) -- Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has been approved by the Food and Drug Administration for treating moderate to severe obstructive sleep apnea.

The agency issued its decision on Friday, giving the stamp of approval for Zepbound's use among adults with obesity for use in combination with a reduced-calorie diet and increased physical activity.

Advertisement